Supplementation of elderly japanese men and women with fucoidan from seaweed increases immune responses to seasonal influenza vaccination

Journal of Nutrition

Volumn 143, Issue 11, 2013, Pages 1794-1798

  Negishi, Hirokuni ^a,c   Mori, Mari ^b,c   Mori, Hideki ^b,c   Yamori, Yukio ^b,c  

^a Aijinkai Healthcare Corporation   (Japan)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^c NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP B ANTIGEN; INFLUENZA VACCINE; PLACEBO; VIRUS VACCINE; FUCOIDIN; IMMUNOLOGICAL ADJUVANT; POLYSACCHARIDE; VIRUS ANTIBODY;

AGED; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; EPIDEMIC; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; MALE; NATURAL KILLER CELL; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SEAWEED; SERUM; VACCINATION; VIRUS STRAIN; VOLUNTEER; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHEMISTRY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA, HUMAN; JAPAN; ORAL DRUG ADMINISTRATION; VERY ELDERLY;

ORTHOMYXOVIRIDAE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ASIAN CONTINENTAL ANCESTRY GROUP; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; JAPAN; KILLER CELLS, NATURAL; MALE; POLYSACCHARIDES; SEAWEED;

EID: 84886824874     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.113.179036     Document Type: Article

References (26)

1. World Health Organization. World health statistics 2010. Geneva: World Health Organization; 2010.
2. Cooper R, Drager C, Elliot K, Fitton JH, Godwin J, Thompson K. GFS, a preparation of Tasmanian Undaria pinnatifida is associated with healing and inhibition of reactivation of herpes. BMC Complement Altern Med. 2002;2:11.
3. Lee JB, Hayashi K, Hashimoto M, Nakano T, Hayashi T. Novel antiviral fucoidan from sporophyll of Undaria pinnatifida (Mekabu). Chem Pharm Bull (Tokyo). 2004;52:1091-4.
4. Hayashi T, Hayashi K, Kanekiyo K, Ohta Y, Lee J-B. Promising antiviral glyco-molecules from an edible alga. In: Torrence P. F., editor. Combating the threat of pandemic influenza: drug discovery approaches. New York: John Wiley & Sons; 2007. p.166-182.
5. Hayashi K, Nakano T, Hashimoto M, Kanekiyo K, Hayashi T. Defensive effects of a fucoidan from brown alga Undaria pinnatifida against herpes simplex virus infection. Int Immunopharmacol. 2008;8: 109-16.
6. Hayashi K, Lee JB, Nakano T, Hayashi T. Anti-influenza A virus characteristics of a fucoidan from sporophyll of Undaria pinnatifida in mice with normal and compromised immunity. Microbes Infect. 2013; 15:302-9.
7. Cumashi A, Ushakova NA, Preobrazhenskaya ME, D'Incecco A, Piccoli A, Totani L, Tinari N, Morozevich GE, Berman AE, Bilan MI, et al. Consorzio Interuniversitario Nazionale per la Bio-Oncologia, Italy. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology. 2007;17:541-52.
8. Maruyama H, Tamauchi H, Hashimoto M, Nakano T. Antitumor activity and immune response of Mekabu fucoidan extracted from sporophyll of Undaria pinnatifida. In Vivo. 2003;17:245-9.
9. Maruyama H, Tamauchi H, Iizuka M, Nakano T. The role of NK cells in antitumor activity of dietary fucoidan from Undaria pinnatifida sporophylls (Mekabu). Planta Med. 2006;72:1415-7.
10. World Health Organization. DG statement following the meeting of the Emergency Committee. Geneva: World Health Organization; June, 2009. Available from: http://www.who.int/csr/disease/swineflu/4th_meeting_ihr/en/index.html. Accessed 16 Jul 2010.
11. World Health Organization. H5N1 avian influenza: timeline of major events. Geneva: World Health Organization; 2010. Available from: http://www.who.int/csr/disease/avian_influenza/2010_06_29_h5n1_ avian_influenza_timeline_updates.pdf . Accessed 16 Jul 2010.
12. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-86.
13. European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccine. Brussels: European Commission, Enterprise and Industry; March 1997. Available from: http://www.ema.europa.eu/pdfs/human/bwp/021496en. pdf. Accessed16 Jun 2010.
14. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, Lilac HA, Hall H, Klimov A, Fukuda K. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA. 2000;284:1655-63.
15. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2:659-66.
16. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24:1159-69.
17. Kendal AP, Pereíra MS, Skehel J. Concepts and procedures for laboratory based influenza surveillance. Geneva: World Health Organization; 1982.
18. Bender BS, Johnson MP, Small PA. Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection. Immunology. 1991;72:514-9.
19. Solana R, Alonso MC, Peña J. Natural killer cells in healthy aging. Exp Gerontol. 1999;34:435-43.
20. Bernstein ED, Gardner EM, Abrutyn E, Gross P, Murasko DM. Cytokine production after influenza vaccination in a healthy elderly population. Vaccine. 1998;16:1722-31.
21. Iso H, Date C, Noda H, Yoshimura T, Tamakoshi A., JACC Study Group. Frequency of food intake and estimated nutrient intake among men and women: the JACC study. J Epidemiol. 2005;15: Suppl 1:S24-42.
22. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC. Safety and antigenicity of non-adjuvanted and MF59- adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet. 2001;357:1937-43.
23. Leroux-Roels I, Borkowaki A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster JM, Leroux-Roels G. Antigen sparing and crossreactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370: 580-9.
24. Meydani SN, Barklund MP, Liu S, Meydani M, Miller RA, Cannon JG, Morrow FD, Rocklin R, Blumberg JB. Vitamin E supplementation enhances cell-mediated immunity in healthy elderly subjects. Am J Clin Nutr. 1990;52:557-63.
25. Girodon F, Galan P, Monget AL, Boutron-Ruault MC, Brunet-Lecomte P, Preziosi P, Arnaud J, Manuguerra JC, Herchberg S. Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: a randomized controlled trial. Arch Intern Med. 1999;159:748-54.
26. Olivares M, Díaz-Ropero MP, Sierra S, Lara-Villoslada F, Fonollá J, Navas M, Rodríguez JM, Xaus J. Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutrition. 2007;23:254-60.